Metabolic reprogramming of oncogene-addicted cancer cells to OXPHOS as a mechanism of drug resistance
MetadataShow full item record
© 2018 The Authors The ability to selectively eradicate oncogene-addicted tumors while reducing systemic toxicity has endeared targeted therapies as a treatment strategy. Nevertheless, development of acquired resistance limits the benefits and durability of such a regime. Here we report evidence of enhanced reliance on mitochondrial oxidative phosphorylation (OXPHOS) in oncogene-addicted cancers manifesting acquired resistance to targeted therapies. To that effect, we describe a novel OXPHOS targeting activity of the small molecule compound, OPB-51602 (OPB). Of note, a priori treatment with OPB restored sensitivity to targeted therapies. Furthermore, cancer cells exhibiting stemness markers also showed selective reliance on OXPHOS and enhanced sensitivity to OPB. Importantly, in a subset of patients who developed secondary resistance to EGFR tyrosine kinase inhibitor (TKI), OPB treatment resulted in decrease in metabolic activity and reduction in tumor size. Collectively, we show here a switch to mitochondrial OXPHOS as a key driver of targeted drug resistance in oncogene-addicted cancers. This metabolic vulnerability is exploited by a novel OXPHOS inhibitor, which also shows promise in the clinical setting.
Showing items related by title, author, creator and subject.
Ferro, R.; Falasca, Marco (2014)Pancreatic cancer is a highly aggressive tumour that is very resistant to treatments and it is rarely diagnosed early because of absence of specific symptoms. Therefore, the prognosis for this disease is very poor and it ...
Sethi, G.; Shanmugam, M.; Warrier, S.; Merarchi, M.; Arfuso, Frank; Kumar, A.; Bishayee, A. (2018)© 2018 by the authors. Licensee MDPI, Basel, Switzerland. Novel and alternative options are being adopted to combat the initiation and progression of human cancers. One of the approaches is the use of molecules isolated ...
Shin, E.; Hay, H.; Lee, M.; Goh, J.; Tan, T.; Sen, Y.; Lim, S.; Yousef, E.; Ong, H.; Thike, A.; Kong, X.; Wu, Z.; Mendoz, E.; Sun, W.; Salto-Tellez, M.; Lim, C.; Lobie, P.; Lim, Y.; Yap, C.; Zeng, Q.; Sethi, G.; Lee, M.; Tan, P.; Goh, B.; Miller, L.; Thiery, J.; Zhu, T.; Gaboury, L.; Tan, P.; Hui, K.; Yip, G.; Miyamoto, S.; Kumar, Alan Prem; Tergaonkar, V. (2014)Despite advancement in breast cancer treatment, 30% of patients with early breast cancers experience relapse with distant metastasis. It is a challenge to identify patients at risk for relapse; therefore, the identification ...